199 related articles for article (PubMed ID: 34171451)
1. Second malignancy probabilities in prostate cancer patients treated with SBRT and other contemporary radiation techniques.
Dee EC; Muralidhar V; King MT; Martin NE; D'Amico AV; Mouw KW; Orio PF; Nguyen PL; Leeman JE
Radiother Oncol; 2021 Aug; 161():241-250. PubMed ID: 34171451
[TBL] [Abstract][Full Text] [Related]
2. Secondary cancers after intensity-modulated radiotherapy, brachytherapy and radical prostatectomy for the treatment of prostate cancer: incidence and cause-specific survival outcomes according to the initial treatment intervention.
Zelefsky MJ; Pei X; Teslova T; Kuk D; Magsanoc JM; Kollmeier M; Cox B; Zhang Z
BJU Int; 2012 Dec; 110(11):1696-701. PubMed ID: 22889401
[TBL] [Abstract][Full Text] [Related]
3. Use, complications, and costs of stereotactic body radiotherapy for localized prostate cancer.
Halpern JA; Sedrakyan A; Hsu WC; Mao J; Daskivich TJ; Nguyen PL; Golden EB; Kang J; Hu JC
Cancer; 2016 Aug; 122(16):2496-504. PubMed ID: 27224858
[TBL] [Abstract][Full Text] [Related]
4. Commentary on "secondary cancers after intensity-modulated radiotherapy, brachytherapy, and radical prostatectomy for the treatment of prostate cancer: incidence and cause-specific survival outcomes according to the initial treatment intervention." Zelefsky MJ, Pei X, Teslova T, Kuk D, Magsanoc JM, Kollmeier M, Cox B, Zhang Z. Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY.: BJU Int 2012;110:1696-701. doi: 10.1111/j.1464-410X.2012.11385.x. [Epub 2012 Aug 13].
Gottschalk A
Urol Oncol; 2014 Feb; 32(2):209. PubMed ID: 24445290
[TBL] [Abstract][Full Text] [Related]
5. Outcomes of treatment for localized prostate cancer in a single institution: comparison of radical prostatectomy and radiation therapy by propensity score matching analysis.
Hayashi N; Osaka K; Muraoka K; Hasumi H; Makiyama K; Kondo K; Nakaigawa N; Yao M; Mukai Y; Sugiura M; Takano S; Ito E; Kaizu H; Koike I; Hata M; Taguri M; Miyoshi Y; Izumi K; Kawahara T; Uemura H
World J Urol; 2020 Oct; 38(10):2477-2484. PubMed ID: 31875247
[TBL] [Abstract][Full Text] [Related]
6. Stereotactic Body Radiation Therapy and High-Dose-Rate Brachytherapy Boost in Combination With Intensity Modulated Radiation Therapy for Localized Prostate Cancer: A Single-Institution Propensity Score Matched Analysis.
Chen WC; Li Y; Lazar A; Altun A; Descovich M; Nano T; Ziemer B; Sudhyadhom A; Cunha A; Thomas H; Gottschalk A; Hsu IC; Roach M
Int J Radiat Oncol Biol Phys; 2021 Jun; 110(2):429-437. PubMed ID: 33385496
[TBL] [Abstract][Full Text] [Related]
7. SBRT and HDR brachytherapy produce lower PSA nadirs and different PSA decay patterns than conventionally fractionated IMRT in patients with low- or intermediate-risk prostate cancer.
Kishan AU; Wang PC; Upadhyaya SK; Hauswald H; Demanes DJ; Nickols NG; Kamrava M; Sadeghi A; Kupelian PA; Steinberg ML; Prionas ND; Buyyounouski MK; King CR
Pract Radiat Oncol; 2016; 6(4):268-275. PubMed ID: 26850649
[TBL] [Abstract][Full Text] [Related]
8. Comparative Toxicities and Cost of Intensity-Modulated Radiotherapy, Proton Radiation, and Stereotactic Body Radiotherapy Among Younger Men With Prostate Cancer.
Pan HY; Jiang J; Hoffman KE; Tang C; Choi SL; Nguyen QN; Frank SJ; Anscher MS; Shih YT; Smith BD
J Clin Oncol; 2018 Jun; 36(18):1823-1830. PubMed ID: 29561693
[TBL] [Abstract][Full Text] [Related]
9. Exploring Value From the Patient's Perspective Between Modern Radiation Therapy Modalities for Localized Prostate Cancer.
Shaverdian N; Verruttipong D; Wang PC; Kishan AU; Demanes DJ; McCloskey S; Kupelian P; Steinberg ML; King CR
Int J Radiat Oncol Biol Phys; 2017 Mar; 97(3):516-525. PubMed ID: 28126301
[TBL] [Abstract][Full Text] [Related]
10. Patient-reported quality of life after stereotactic body radiotherapy (SBRT), intensity modulated radiotherapy (IMRT), and brachytherapy.
Evans JR; Zhao S; Daignault S; Sanda MG; Michalski J; Sandler HM; Kuban DA; Ciezki J; Kaplan ID; Zietman AL; Hembroff L; Feng FY; Suy S; Skolarus TA; McLaughlin PW; Wei JT; Dunn RL; Finkelstein SE; Mantz CA; Collins SP; Hamstra DA;
Radiother Oncol; 2015 Aug; 116(2):179-84. PubMed ID: 26276528
[TBL] [Abstract][Full Text] [Related]
11. Incidence of second malignancies in prostate cancer patients treated with low-dose-rate brachytherapy and radical prostatectomy.
Hamilton SN; Tyldesley S; Hamm J; Jiang WN; Keyes M; Pickles T; Lapointe V; Kahnamelli A; McKenzie M; Miller S; Morris WJ
Int J Radiat Oncol Biol Phys; 2014 Nov; 90(4):934-41. PubMed ID: 25240272
[TBL] [Abstract][Full Text] [Related]
12. Erectile function after stereotactic body radiotherapy for localized prostate cancer.
Dess RT; Hartman HE; Aghdam N; Jackson WC; Soni PD; Abugharib AE; Suy S; Desai NB; Zumsteg ZS; Mehra R; Morgan TM; Feng FY; Hamstra DA; Schipper MJ; Collins SP; Spratt DE
BJU Int; 2018 Jan; 121(1):61-68. PubMed ID: 28710895
[TBL] [Abstract][Full Text] [Related]
13. Stereotactic body radiation therapy for prostate cancer-a review.
Haque W; Butler EB; Teh BS
Chin Clin Oncol; 2017 Sep; 6(Suppl 2):S10. PubMed ID: 28917248
[TBL] [Abstract][Full Text] [Related]
14. Stereotactic body radiation therapy versus intensity-modulated radiation therapy for prostate cancer: comparison of toxicity.
Yu JB; Cramer LD; Herrin J; Soulos PR; Potosky AL; Gross CP
J Clin Oncol; 2014 Apr; 32(12):1195-201. PubMed ID: 24616315
[TBL] [Abstract][Full Text] [Related]
15. Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy Boost and Disease Progression and Mortality in Patients With Gleason Score 9-10 Prostate Cancer.
Kishan AU; Cook RR; Ciezki JP; Ross AE; Pomerantz MM; Nguyen PL; Shaikh T; Tran PT; Sandler KA; Stock RG; Merrick GS; Demanes DJ; Spratt DE; Abu-Isa EI; Wedde TB; Lilleby W; Krauss DJ; Shaw GK; Alam R; Reddy CA; Stephenson AJ; Klein EA; Song DY; Tosoian JJ; Hegde JV; Yoo SM; Fiano R; D'Amico AV; Nickols NG; Aronson WJ; Sadeghi A; Greco S; Deville C; McNutt T; DeWeese TL; Reiter RE; Said JW; Steinberg ML; Horwitz EM; Kupelian PA; King CR
JAMA; 2018 Mar; 319(9):896-905. PubMed ID: 29509865
[TBL] [Abstract][Full Text] [Related]
16. Patient-reported Quality of Life Following Stereotactic Body Radiotherapy and Conventionally Fractionated External Beam Radiotherapy Compared with Active Surveillance Among Men with Localized Prostate Cancer.
Moon DH; Basak RS; Usinger DS; Dickerson GA; Morris DE; Perman M; Lim M; Wibbelsman T; Chang J; Crawford Z; Broughman JR; Godley PA; Chen RC
Eur Urol; 2019 Sep; 76(3):391-397. PubMed ID: 30857758
[TBL] [Abstract][Full Text] [Related]
17. Time-driven activity-based cost comparison of prostate cancer brachytherapy and intensity-modulated radiation therapy.
Dutta SW; Bauer-Nilsen K; Sanders JC; Trifiletti DM; Libby B; Lash DH; Lain M; Christodoulou D; Hodge C; Showalter TN
Brachytherapy; 2018; 17(3):556-563. PubMed ID: 29519605
[TBL] [Abstract][Full Text] [Related]
18. Incidence of secondary cancer development after high-dose intensity-modulated radiotherapy and image-guided brachytherapy for the treatment of localized prostate cancer.
Zelefsky MJ; Housman DM; Pei X; Alicikus Z; Magsanoc JM; Dauer LT; St Germain J; Yamada Y; Kollmeier M; Cox B; Zhang Z
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(3):953-9. PubMed ID: 22172904
[TBL] [Abstract][Full Text] [Related]
19. Second malignancy probabilities in patients with prostate cancer treated with whole pelvis radiation therapy versus prostate only radiation therapy.
Cho HL; Murthy V; Mouw KW; D'Amico AV; Nguyen PL; Leeman JE; Dee EC
Prostate; 2022 Aug; 82(11):1098-1106. PubMed ID: 35652585
[TBL] [Abstract][Full Text] [Related]
20. Pattern of solid and hematopoietic second malignancy after local therapy for prostate cancer.
Wang C; King CR; Kamrava M; Iwamoto KS; Chen AM; Low D; Kupelian PA; Steinberg ML
Radiother Oncol; 2017 Apr; 123(1):133-138. PubMed ID: 28187996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
